Figure 1: MSCs therapeutic efficiency depends upon donor source (1) and stromal tissue source variability (2), and Cell manufacturing process (3). Immune matching, metabolic fitness and route of delivery regulate MSCs persistence inside recipient (5). Before in vivo administration, chemical licensing/ genetic modification (4) is the key strategy to improve graft cell survival (5b)
Tables at a glance
Figures at a glance